Puberty blockers should remain a clinical option for certain children with gender dysphoria despite limited evidence about their benefits and harms, according to long-awaited national advice.

Puberty blockers should remain a clinical option for certain children with gender dysphoria despite limited evidence about their benefits and harms, according to long-awaited national advice.